| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$22.7M | ROE | −176.32% |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $10.2M | Trading Days | 2522 |
| 52W High | 13.48 |
| 52W Low | 0.89 |
| % Off High | −91.10% |
| YTD | −77.19% | 1Y | −86.06% |
| 3Y | −97.61% | 5Y | −99.52% |
| 10Y | −99.66% | Since incept. (ann.) | −43.26% |
| Ann. Volatility (1Y) | 117.25% | Ann. Volatility (3Y) | 117.95% |
| Sharpe (1Y) | −1.11 | Sharpe (3Y) | −0.48 |
| Max Drawdown (1Y) | −92.53% | Max Drawdown (3Y) | −98.96% |
| Beta (3Y, vs SPY) | 0.95 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| BCLI | BRAINSTORM CELL THERAPEUTICS INC. | $9.9M | — |
| INAB | IN8BIO, INC. | $10.9M | — |
| INTS | INTENSITY THERAPEUTICS, INC. | $12.3M | — |
| PASG | Passage BIO, Inc. | $14.7M | — |
| ZIVO | Zivo Bioscience, Inc. | $15.6M | — |
| PMCB | PharmaCyte Biotech, Inc. | $6.3M | 0.2 |
| JSPR | Jasper Therapeutics, Inc. | $17.7M | — |
| PLUR | Pluri Inc. | $18.1M | — |
| LIMN | Liminatus Pharma, Inc. | $4.7M | — |
| TVGN | Tevogen Bio Holdings Inc. | $23.4M | — |
| APTOF | Aptose Biosciences Inc. | $4.3M |
| GRML | Greenland Mines Ltd | $24.1M | — |
